2 High-Yield Dividend Stocks to Buy Right Now

The article highlights Pfizer (PFE) and Medical Properties Trust (MPW) as high-yield dividend stocks for potential investment. Pfizer, despite facing challenges from waning coronavirus market performance and upcoming patent cliffs, is investing in its pipeline, including oncology through the acquisition of Seagen, and cost management, while maintaining a 7.5% forward yield. Medical Properties Trust, a healthcare REIT, is recovering from tenant bankruptcies by diversifying its portfolio with new long-term leases and improving its balance sheet, offering a 6.3% yield, although its shares remain down over the past three years.

Analysis

The search for dividend yields exceeding the S&P 500's average of 1.3% has brought Pfizer (PFE) and Medical Properties Trust (MPW) into focus, both offering higher current yields while navigating significant operational and strategic transitions. Pfizer's shares have faced pressure over the past three years due to waning revenue from its coronavirus products and impending patent expirations for key drugs like Eliquis. In response, Pfizer is pursuing growth through its pipeline, notably strengthened by the $43 billion acquisition of oncology specialist Seagen in 2023, and is implementing cost management programs aimed at margin expansion by 2027. Management has reiterated commitment to its 7.5% forward dividend yield, contingent on the success of these initiatives. Medical Properties Trust, a healthcare-focused REIT, is in a recovery phase after significant challenges, including tenant bankruptcies that led to revenue declines, FFO reduction, and a necessary dividend cut. The company reports progress in diversifying its tenant base, securing new long-term leases averaging approximately 18 years, and improving its balance sheet through asset sales and debt refinancing. MPW currently offers a 6.3% forward dividend yield and its stock has shown recent recovery, though it remains significantly below its three-year highs and was noted as not being among one particular analyst team's top 10 current buy recommendations, reflecting a cautiously optimistic outlook on its turnaround.

Key Decisions for Investors

• Investors considering Pfizer should weigh its attractive 7.5% forward dividend yield and long-term recovery potential, particularly from its Seagen-enhanced oncology pipeline, against the near-term headwinds from patent cliffs and the multi-year timeline required for its strategic initiatives to fully mature.
• For Medical Properties Trust, the 6.3% yield and reported progress in its turnaround, including tenant diversification and balance sheet repair, may appeal to those comfortable with recovery narratives, but this should be balanced with diligent monitoring of its sustained operational performance and the context of its recent financial restructuring.
• Those allocating capital to high-yield opportunities such as PFE or MPW should closely monitor key execution milestones: for Pfizer, advancements in its oncology pipeline and achievement of cost-saving targets; for MPW, continued progress in stabilizing revenues, managing its debt profile, and maintaining tenant relationships.